Skip to main content

MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products

Written by Customer Service on . Posted in Public Companies.

Agreement expands offering to include additional sheet, particulate and flowable products

MARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Summit Products Group (“Summit”) to distribute three innovative, 510(k) cleared products that complement the Company’s leading Surgical & Wound product portfolio: Hydrelix, NovaForm®, and G4Derm® Plus.

About the products:

  • Hydrelix Collagen Matrix is a sterile, Type 1 collagen powder, comprised of soluble modified bovine collagen. The product is formulated from hydrolyzed and modified collagens in powdered form, bypassing the need for further enzymatic degradation by the body. This allows the bioactive components of collagen to be readily available at the wound site, facilitating a more direct and efficient therapeutic effect.
  • NovaForm Wound Matrix is a proprietary bioglass and collagen-based wound dressing intended for use in the management of partial and full-thickness wounds, such as pressure ulcers, venous ulcers, diabetic ulcers and surgical wounds. The highly conformable, bioengineered matrix is designed to protect the wound, while maintaining a moist environment that supports the body’s natural healing process.
  • G4Derm Plus is a flowable peptide matrix engineered for rapid, protected wound closure. The product forms a 3D scaffold that mimics the human extracellular matrix (ECM) and serves as an antibacterial barrier that protects the wound. The biomimetic matrix is uniquely positioned to simultaneously spur tissue regrowth and control bioburden.

“We are excited to announce this distribution agreement with Summit to meaningfully expand our product offering with Hydrelix, NovaForm and G4Derm Plus. These are innovative xenograft and synthetic products that strengthen our ability to serve the Surgical & Wound markets,” stated Kim Moller, MIMEDX Chief Commercial Officer. “As the landscape of this market continues to evolve, MIMEDX remains a leader in supporting customers and their patients with proven products.”

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

About Summit Products Group
Summit Products Group is a specialized healthcare company dedicated to advancing surgical and regenerative solutions. With a mission to innovate, cultivate and elevate market-leading solutions, Summit Products Group identifies breakthrough products, guides them through regulatory pathways and delivers them to providers who demand clinical excellence. Through strategic partnerships, integrated logistics, and a deep understanding of FDA compliance, Summit Products Group brings clarity and confidence to the commercialization of novel technologies. On the web: www.summitproductsgroup.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.